Opinion|Videos|May 29, 2025
An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC
Panelists discuss how nogapendekin alfa, an intravesical immunotherapy that stimulates a localized immune response, combined with BCG therapy, provides a novel dual approach for treating BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), targeting both local and systemic immune responses.
Advertisement
Episodes in this series
Physician Summary:
Nogapendekin Alfa Inbakicept-pmln
- Mechanism of Action: Nogapendekin alfa is an immunotherapy that combines a recombinant protein designed to stimulate the immune system with the aim of inducing a localized immune response against bladder cancer cells, particularly for carcinoma in situ and papillary tumors. It acts by enhancing the body’s immune response to cancer cells, stimulating an inflammatory response that targets the tumor. This approach helps activate the immune system without requiring systemic exposure.
- Administration: Nogapendekin alfa is administered intravesically, with patients typically receiving the therapy directly into the bladder via catheter. After intravesical administration, it is followed by a course of intravesical BCG therapy, which further primes the immune response and increases efficacy by maintaining bladder immunity over time.
This combination approach offers a novel, dual immunotherapeutic strategy for BCG-unresponsive NMIBC, potentially enhancing both local and systemic immune responses to bladder cancer.
Advertisement
Related to this article
Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.
Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.
enGene expects to initiate a BLA submission by the end of 2026.
The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
Detalimogene shows continued activity in BCG-unresponsive NMIBC
4
Q&A: Where ProACT fits in the male stress urinary incontinence algorithm
5